| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
PMV Pharmaceuticals, Inc.
13G
PMVP · 69353Y103
|
9.9% |
9/15/2026
Event 9/2/2026
|
|||
| Samsara BioCapital, L.P. | 5.0% | ||||
| Samsara BioCapital GP, LLC | 5.0% | ||||
| Samsara Opportunity Fund, L.P. | 5.0% | ||||
| Samsara Opportunity Fund GP, LLC | 5.0% | ||||
| Srinivas Akkaraju | 9.9% | ||||
|
Eloxx Pharmaceuticals, Inc.
13G
ELOX · 29014R301
|
9.9% |
8/14/2026
Event 6/10/2026
|
|||
| Samsara BioCapital, L.P. | 5.0% | ||||
| Samsara BioCapital GP, LLC | 5.0% | ||||
| Samsara Opportunity Fund, L.P. | 5.0% | ||||
| Samsara Opportunity Fund GP, LLC | 5.0% | ||||
| Srinivas Akkaraju | 9.9% | ||||
|
Rani Therapeutics Holdings, Inc
13D/A
Amendment 1
RANI · 753018100
|
9.9% |
5/28/2026
Event 5/26/2026
|
|||
| Samsara BioCapital, L.P. | 5.0% | ||||
| Samsara BioCapital GP, LLC | 5.0% | ||||
| Samsara Opportunity Fund, L.P. | 5.0% | ||||
| Samsara Opportunity Fund GP, LLC | 5.0% | ||||
| Srinivas Akkaraju | 9.9% | ||||
|
Kalaris Therapeutics, Inc.
13D/A
Amendment 3
KLRS · 482929106
|
54.2% |
5/22/2026
Event 5/20/2026
|
|||
| Samsara BioCapital, L.P. | 44.8% | ||||
| Samsara BioCapital GP, LLC | 44.9% | ||||
| Samsara Opportunity Fund, L.P. | 9.3% | ||||
| Samsara Opportunity Fund GP, LLC | 9.3% | ||||
| Srinivas Akkaraju | 54.2% | ||||
|
Sutro Biopharma, Inc.
13G
STRO · 869367201
|
6.4% |
5/15/2026
Event 2/11/2026
|
|||
| Samsara BioCapital, L.P. | 2.5% | ||||
| Samsara BioCapital GP, LLC | 2.5% | ||||
| Samsara Opportunity Fund, L.P. | 3.9% | ||||
| Samsara Opportunity Fund GP, LLC | 3.9% | ||||
| Srinivas Akkaraju | 6.4% | ||||
|
Kalaris Therapeutics, Inc.
13D/A
Amendment 2
KLRS · 482929106
|
56.5% |
2/17/2026
Event 12/18/2025
|
|||
| Samsara BioCapital, L.P. | 47.9% | ||||
| Samsara BioCapital GP, LLC | 47.9% | ||||
| Samsara Opportunity Fund, L.P. | 8.6% | ||||
| Samsara Opportunity Fund GP, LLC | 8.6% | ||||
| Srinivas Akkaraju | 56.5% | ||||
|
Spyglass Pharma, Inc.
13G
SGP · 85220G109
|
6.3% |
2/17/2026
Event 2/9/2026
|
|||
| Samsara BioCapital, L.P. | 4.5% | ||||
| Samsara BioCapital GP, LLC | 4.5% | ||||
| Samsara Opportunity Fund, L.P. | 1.9% | ||||
| Samsara Opportunity Fund GP, LLC | 1.9% | ||||
| Srinivas Akkaraju | 6.3% | ||||
|
Alumis Inc.
13D/A
Amendment 1
ALMS · 022307102
|
5.4% |
1/13/2026
Event 1/9/2026
|
|||
| Samsara BioCapital, L.P. | 3.8% | ||||
| Samsara BioCapital GP, LLC | 3.8% | ||||
| Samsara Opportunity Fund, L.P. | 1.6% | ||||
| Samsara Opportunity Fund GP, LLC | 1.6% | ||||
| Srinivas Akkaraju | 5.4% | ||||
|
Kalaris Therapeutics, Inc.
13D/A
Amendment 1
KLRS · 482929106
|
56.5% |
12/22/2025
Event 12/22/2025
|
|||
| Samsara BioCapital, L.P. | 50.0% | ||||
| Samsara BioCapital GP, LLC | 50.0% | ||||
| Samsara Opportunity Fund, L.P. | 6.5% | ||||
| Samsara Opportunity Fund GP, LLC | 6.5% | ||||
| Srinivas Akkaraju | 56.5% | ||||
|
vTv Therapeutics Inc.
13D/A
Amendment 3
VTVT · 918385204
|
9.9% |
12/9/2025
Event 12/8/2025
|
|||
| Samsara BioCapital, L.P. | 6.2% | ||||
| Samsara BioCapital GP, LLC | 6.2% | ||||
| Samsara Opportunity Fund, L.P. | 3.8% | ||||
| Samsara Opportunity Fund GP, LLC | 3.8% | ||||
| Srinivas Akkaraju | 9.9% | ||||
|
Alumis Inc.
13D
ALMS · 022307102
|
5.3% |
11/24/2025
Event 11/18/2025
|
|||
| Samsara BioCapital, L.P. | 4.6% | ||||
| Samsara BioCapital GP, LLC | 4.6% | ||||
| Samsara Opportunity Fund, L.P. | 0.7% | ||||
| Samsara Opportunity Fund GP, LLC | 0.7% | ||||
| Srinivas Akkaraju | 5.3% | ||||
|
Nkarta, Inc.
13D/A
Amendment 3
NKTX · 65487U108
|
4.9% |
11/24/2025
Event 11/20/2025
|
|||
| Samsara BioCapital, L.P. | 4.9% | ||||
| Samsara BioCapital GP, LLC | 4.9% | ||||
| Srinivas Akkaraju | 4.9% | ||||
|
Inventiva S.A.
13D/A
Amendment 1
IVA · 46124U107
|
7.4% |
11/19/2025
Event 11/17/2025
|
|||
| Samsara BioCapital, L.P. | 4.5% | ||||
| Samsara BioCapital GP, LLC | 4.5% | ||||
| Samsara Opportunity Fund, L.P. | 2.8% | ||||
| Samsara Opportunity Fund GP, LLC | 2.8% | ||||
| Srinivas Akkaraju | 7.4% | ||||
|
Alumis Inc.
13D/A
Amendment 2
ALMS · 022307102
|
4.9% |
11/17/2025
Event 11/13/2025
|
|||
| Samsara BioCapital, L.P. | 4.6% | ||||
| Samsara BioCapital GP, LLC | 4.6% | ||||
| Samsara Opportunity Fund, L.P. | 0.3% | ||||
| Samsara Opportunity Fund GP, LLC | 0.3% | ||||
| Srinivas Akkaraju | 4.9% | ||||
|
CARGO Therapeutics, Inc.
13G/A
Amendment 2
CRGX · 14179K101
|
0% |
11/14/2025
Event 9/30/2025
|
|||
| Samsara BioCapital, L.P. | 0% | ||||
| Samsara BioCapital GP, LLC | 0% | ||||
| Srinivas Akkaraju | 0% | ||||
|
Rani Therapeutics Holdings, Inc
13D
RANI · 753018100
|
9.9% |
10/30/2025
Event 10/23/2025
|
|||
| Samsara BioCapital, L.P. | 5.0% | ||||
| Samsara BioCapital GP, LLC | 5.0% | ||||
| Samsara Opportunity Fund, L.P. | 5.0% | ||||
| Samsara Opportunity Fund GP, LLC | 5.0% | ||||
| Srinivas Akkaraju | 9.9% | ||||
|
Inventiva S.A.
13D
IVA · 46124U107
|
5.9% |
10/21/2025
Event 5/7/2025
|
|||
| Samsara BioCapital, L.P. | 5.9% | ||||
| Samsara BioCapital GP, LLC | 5.9% | ||||
| Srinivas Akkaraju | 5.9% | ||||
|
Scholar Rock Holding Corp
13D/A
Amendment 3
SRRK · 80706P103
|
7.2% |
10/7/2025
Event 10/3/2025
|
|||
| Samsara BioCapital, L.P. | 6.6% | ||||
| Samsara BioCapital GP, LLC | 6.6% | ||||
| Samsara Opportunity Fund, L.P. | 0.5% | ||||
| Samsara Opportunity Fund GP, LLC | 0.5% | ||||
| Srinivas Akkaraju | 7.2% | ||||
|
vTv Therapeutics Inc.
13D/A
Amendment 2
VTVT · 918385204
|
9.9% |
9/25/2025
Event 9/22/2025
|
|||
| Samsara BioCapital, L.P. | 6.5% | ||||
| Samsara BioCapital GP, LLC | 6.5% | ||||
| Samsara Opportunity Fund, L.P. | 3.5% | ||||
| Samsara Opportunity Fund GP, LLC | 3.5% | ||||
| Srinivas Akkaraju | 9.9% | ||||
|
Mineralys Therapeutics, Inc.
13D/A
Amendment 3
MLYS · 603170101
|
8.2% |
9/8/2025
Event 9/4/2025
|
|||
| Samsara BioCapital, L.P. | 7.3% | ||||
| Samsara BioCapital GP, LLC | 7.3% | ||||
| Samsara Opportunity Fund, L.P. | 0.8% | ||||
| Samsara Opportunity Fund GP, LLC | 0.8% | ||||
| Srinivas Akkaraju | 8.2% | ||||
|
vTv Therapeutics Inc.
13D/A
Amendment 1
VTVT · 918385204
|
9.9% |
9/3/2025
Event 8/29/2025
|
|||
| Samsara BioCapital, L.P. | 9.9% | ||||
| Samsara BioCapital GP, LLC | 9.9% | ||||
| Srinivas Akkaraju | 9.9% | ||||
|
Leap Therapeutics, Inc.
13G/A
Amendment 1
CYPH · 52187K200
|
0% |
8/14/2025
Event 6/30/2025
|
|||
| Samsara BioCapital, L.P. | 0% | ||||
| Samsara BioCapital GP, LLC | 0% | ||||
| Srinivas Akkaraju | 0% | ||||
|
OnKure Therapeutics, Inc.
13G/A
Amendment 1
OKUR · 68277Q105
|
0% |
8/14/2025
Event 6/30/2025
|
|||
| Samsara BioCapital, L.P. | 0% | ||||
| Samsara BioCapital GP, LLC | 0% | ||||
| Srinivas Akkaraju | 0% | ||||
|
Palvella Therapeutics, Inc.
13G/A
Amendment 1
PVLA · 697947109
|
3.1% |
8/14/2025
Event 6/30/2025
|
|||
| Samsara BioCapital, L.P. | 3.1% | ||||
| Samsara BioCapital GP, LLC | 3.1% | ||||
| Srinivas Akkaraju | 3.1% | ||||
|
Alumis Inc.
13D/A
Amendment 1
ALMS · 022307102
|
5.0% |
5/23/2025
Event 5/21/2025
|
|||
| Samsara BioCapital, L.P. | 5.0% | ||||
| Samsara BioCapital GP, LLC | 5.0% | ||||
| Srinivas Akkaraju | 5.0% | ||||
|
Syros Pharmaceuticals, Inc.
13D/A
Amendment 2
SYRS · 87184Q206
|
2.6% |
3/27/2025
Event 11/18/2024
|
|||
| Samsara BioCapital, L.P. | 2.6% | ||||
| Samsara BioCapital GP, LLC | 2.6% | ||||
| Srinivas Akkaraju | 2.6% | ||||
|
Kalaris Therapeutics, Inc.
13D
KLRS · 482929106
|
61.2% |
3/25/2025
Event 3/18/2025
|
|||
| Samsara BioCapital, L.P. | 61.2% | ||||
| Samsara BioCapital GP, LLC | 61.2% | ||||
| Srinivas Akkaraju | 61.2% | ||||
|
Mineralys Therapeutics, Inc.
13D/A
Amendment 2
MLYS · 603170101
|
9.1% |
3/17/2025
Event 3/13/2025
|
|||
| Samsara BioCapital, L.P. | 9.0% | ||||
| Samsara BioCapital GP, LLC | 9.0% | ||||
| Srinivas Akkaraju | 9.1% | ||||
|
IO Biotech, Inc.
13G/A
Amendment 1
IOBTQ · 449778109
|
3.8% |
2/14/2025
Event 12/31/2024
|
|||
| Samsara BioCapital, L.P. | 3.8% | ||||
| Samsara BioCapital GP, LLC | 3.8% | ||||
| Srinivas Akkaraju | 3.8% | ||||
|
Palvella Therapeutics, Inc.
13G
PVLA · 697947109
|
6.1% |
12/20/2024
Event 12/13/2024
|
|||
| Samsara BioCapital, L.P. | 6.1% | ||||
| Samsara BioCapital GP, LLC | 6.1% | ||||
| Srinivas Akkaraju | 6.1% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.